Lifesci Capital Comments on Scholar Rock Q2 Earnings

Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) - Investment analysts at Lifesci Capital issued their Q2 2025 earnings estimates for Scholar Rock in a report released on Tuesday, June 3rd. Lifesci Capital analyst D. Kennedy forecasts that the company will post earnings of ($0.92) per share for the quarter. Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. Lifesci Capital also issued estimates for Scholar Rock's Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.29) EPS, Q1 2026 earnings at ($0.65) EPS, Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($1.59) EPS.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same period last year, the firm posted ($0.59) EPS.

Separately, Wedbush restated an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a report on Wednesday, May 14th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Scholar Rock currently has a consensus rating of "Buy" and an average target price of $42.67.

Scholar Rock Trading Down 0.1%

NASDAQ:SRRK traded down $0.02 during trading hours on Thursday, reaching $34.23. 1,826,713 shares of the company were exchanged, compared to its average volume of 1,279,901. The firm has a market cap of $3.25 billion, a price-to-earnings ratio of -14.57 and a beta of 0.37. The stock has a 50 day simple moving average of $30.29 and a 200 day simple moving average of $36.10. Scholar Rock has a 52-week low of $6.76 and a 52-week high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Hedge Funds Weigh In On Scholar Rock

Institutional investors and hedge funds have recently bought and sold shares of the stock. Global Retirement Partners LLC lifted its holdings in Scholar Rock by 584.7% in the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after buying an additional 766 shares in the last quarter. CWM LLC increased its position in shares of Scholar Rock by 152.8% during the first quarter. CWM LLC now owns 996 shares of the company's stock worth $32,000 after acquiring an additional 602 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of Scholar Rock during the fourth quarter worth about $85,000. Federated Hermes Inc. acquired a new position in shares of Scholar Rock in the first quarter worth about $71,000. Finally, Strs Ohio purchased a new position in Scholar Rock in the first quarter valued at about $77,000. Hedge funds and other institutional investors own 91.08% of the company's stock.

Insiders Place Their Bets

In related news, CFO Edward H. Myles sold 142,292 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $35.62, for a total transaction of $5,068,441.04. Following the completion of the sale, the chief financial officer now directly owns 111,345 shares of the company's stock, valued at approximately $3,966,108.90. This represents a 56.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Katie Peng sold 1,006 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the completion of the sale, the director now directly owns 30,319 shares of the company's stock, valued at $1,043,579.98. The trade was a 3.21% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 181,798 shares of company stock worth $6,284,738 over the last ninety days. 13.30% of the stock is owned by company insiders.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.